Xcout IntelCapricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Subscribe to see Capricor Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Capricor Therapeutics, Inc. at a glance
Capricor Therapeutics, Inc. is a biotech company headquartered in San Diego, United States. It is publicly listed (CAPR) with a market capitalisation of $227.3M. Xcout tracks 22 named people at Capricor Therapeutics, Inc., including Anthony J. Bergmann (Chief Financial Officer & Corporate Treasurer). Xcout recorded 5 job postings from Capricor Therapeutics, Inc. in the last 90 days.
Capricor Therapeutics, Inc. leadership
- Anthony J. BergmannChief Financial Officer & Corporate Treasurer
- AJ BergmannChief Financial Officer
- Kristi A. H. ElliottChief Operating & Science Officer
- Mark AwadallaChief Development Officer
- Michael BinksChief Medical Officer
- Michael MaurerChief Commercial Officer
16 more named people on record for Capricor Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Capricor Therapeutics, Inc.
Xcout recorded 5 job postings from Capricor Therapeutics, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Capricor Therapeutics, Inc.'s hiring signals →
Tech stack
Capricor Therapeutics, Inc. competitors
A few of Capricor Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Angiocrine Bioscience, Inc. is a private, clinical-stage biotechnology company based in San Diego, California, that develops engineered endothelial cell therapies.
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
VST Bio Corp. is a leader in the development of innovative biologics to treat acute and chronic cardiovascular diseases. Headquartered in San Diego, California, the company engages in drug pipelines, patents, and clinical trials.
XyloCor Therapeutics is a clinical-stage biopharmaceutical company headquartered in King of Prussia, Pennsylvania, focused on developing novel gene therapies for advanced coronary artery disease. The company is dedicated to improving patient outcomes through innovative cardiovascular treatments.
ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company located in San Diego, California. The company is committed to developing cutting-edge RNA-targeted therapeutics to treat various genetic and severe diseases. ADARx focuses on translating scientific research into life-saving medicines through its proprietary drug discovery pipeline.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Get Capricor Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Capricor Therapeutics, Inc. in Xcout Intel
- 22 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 5 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access